These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38642827)

  • 1. PYCR3 modulates mtDNA copy number to drive proliferation and doxorubicin resistance in triple-negative breast cancer.
    Zhuang F; Huang S; Liu L
    Int J Biochem Cell Biol; 2024 Jun; 171():106581. PubMed ID: 38642827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MALSU1-mediated regulation of mitochondrial function governs proliferation and doxorubicin resistance in triple-negative breast cancer cells.
    Zhuang F; Huang S; Liu L
    Mol Cell Biochem; 2024 Jun; ():. PubMed ID: 38896203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SMAGP regulates doxorubicin sensitivity in triple-negative breast cancer cells via modulating mitochondrial respiration.
    Xiao H; Yang X; Huang S
    Cancer Chemother Pharmacol; 2023 Jan; 91(1):43-52. PubMed ID: 36436062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive triple negative breast cancers have unique molecular signature on the basis of mitochondrial genetic and functional defects.
    Guha M; Srinivasan S; Raman P; Jiang Y; Kaufman BA; Taylor D; Dong D; Chakrabarti R; Picard M; Carstens RP; Kijima Y; Feldman M; Avadhani NG
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt A):1060-1071. PubMed ID: 29309924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A SRC-slug-TGFβ2 signaling axis drives poor outcomes in triple-negative breast cancers.
    Angel CZ; Beattie S; Hanif EAM; Ryan MP; Guerra Liberal FDC; Zhang SD; Monteith S; Buckley NE; Parker E; Haynes S; McIntyre AJ; Haddock P; Sharifova M; Branco CM; Mullan PB
    Cell Commun Signal; 2024 Sep; 22(1):454. PubMed ID: 39327614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
    Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
    Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer.
    Chen DR; Lu DY; Lin HY; Yeh WL
    Biomed Res Int; 2014; 2014():532161. PubMed ID: 25140317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
    Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
    J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
    Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
    Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
    Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
    Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
    Wei W; Zou Y; Jiang Q; Zhou Z; Ding H; Yan L; Yang S
    Int J Biol Markers; 2018 Jan; 33(1):102-108. PubMed ID: 28623645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability.
    Sirois I; Aguilar-Mahecha A; Lafleur J; Fowler E; Vu V; Scriver M; Buchanan M; Chabot C; Ramanathan A; Balachandran B; Légaré S; Przybytkowski E; Lan C; Krzemien U; Cavallone L; Aleynikova O; Ferrario C; Guilbert MC; Benlimame N; Saad A; Alaoui-Jamali M; Saragovi HU; Josephy S; O'Flanagan C; Hursting SD; Richard VR; Zahedi RP; Borchers CH; Bareke E; Nabavi S; Tonellato P; Roy JA; Robidoux A; Marcus EA; Mihalcioiu C; Majewski J; Basik M
    Mol Cancer Res; 2019 Dec; 17(12):2492-2507. PubMed ID: 31537618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage.
    Chen Y; Feng X; Yuan Y; Jiang J; Zhang P; Zhang B
    Cell Death Dis; 2022 Apr; 13(4):338. PubMed ID: 35414060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
    Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
    J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of miR-335 in triple-negative breast cancer and its effect on chemosensitivity.
    Hao J; Lai M; Liu C
    J BUON; 2019; 24(4):1526-1531. PubMed ID: 31646803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Movement of Mitochondria with Mutant DNA through Extracellular Vesicles Helps Cancer Cells Acquire Chemoresistance.
    Abad E; Lyakhovich A
    ChemMedChem; 2022 Feb; 17(4):e202100642. PubMed ID: 34847299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells.
    Ciocan-Cartita CA; Jurj A; Zanoaga O; Cojocneanu R; Pop LA; Moldovan A; Moldovan C; Zimta AA; Raduly L; Pop-Bica C; Buse M; Budisan L; Virag P; Irimie A; Gomes Dias SM; Berindan-Neagoe I; Braicu C
    J Exp Clin Cancer Res; 2020 Nov; 39(1):241. PubMed ID: 33187552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.